Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients

Giovanni Martinelli, E. Cocorocchio, P. C. Saletti, R. Orecchia, J. Bernier, N. Tradati, P. Santoro, C. Robertson, F. A. Peccatori, E. Zucca, F. Cavalli

Research output: Contribution to journalArticlepeer-review

Abstract

Vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy (CT) with involved field radiotherapy (IFRT) was first described by the Stanford group as an active regimen in early stage Hodgkin's disease (HD). Here, we report our retrospective experience of a modified VBM schedule + IFRT in a similar group of patients. From 1988, 49 patients with stage I-IIA HD received vinblastine (VBL) 6 mg/m2 , bleomycin (BLM) 10IU/m2, methotrexate (MTX 30 mg/m2 day 1,8 every four weeks for three cycles; IFRT was delivered four weeks later followed by three additional cycles of VBM with a dose reduction of BLM (6IU/m2). The regimen was well tolerated, with grade 3-4 neutropenia occurring in 20 patients. No acute or late pulmonary toxicity was recorded in our series. Estimated Freedom from Progression (FFP) and Overall Survival (OS) at five years are 75% (95% CI, 60.1%-92.2%) and 85% (95% CI, 73.6%-98.1%), respectively. In this retrospective analysis, VBM + IFRT treatment with bleomycin dose reduction seems safe and active. Such combination could be considered as first line treatment for early stage HD patients with favorable prognosis and/or not suitable for anthracyclines-containing regimens.

Original languageEnglish
Pages (from-to)1919-1923
Number of pages5
JournalLeukemia and Lymphoma
Volume44
Issue number11
DOIs
Publication statusPublished - Nov 2003

Keywords

  • Bleomycin
  • Combination chemotherapy vinblastine
  • Early stage
  • Hodgkin disease
  • Radiotherapy
  • State I and II

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients'. Together they form a unique fingerprint.

Cite this